Abstract

Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1 Trial

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Tycel J Phillips ... Peter Johnson
Blood | VOL. 136
Tycel J Phillips, et. al.Tycel J Phillips ... Peter Johnson
05 Nov 2020
Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
Stephen Opat ...
Blood | VOL. 136
Stephen Opat, et. al.Stephen Opat ...
05 Nov 2020
Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial
Melody R Becnel ... Nathan Fowler
Blood | VOL. 130
Melody R Becnel, et. al.Melody R Becnel ... Nathan Fowler
25 Jun 2021
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
Pier Luigi Zinzani ...
Blood | VOL. 136
Pier Luigi Zinzani, et. al.Pier Luigi Zinzani ...
05 Nov 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Samuel Bidot ... Andrew L Feldman
Blood | VOL. 143
Samuel Bidot, et. al.Samuel Bidot ... Andrew L Feldman
27 Jun 2024
GM-CSF brings (good) memories
Damien Reynaud
Blood | VOL. 143
Damien ReynaudDamien Reynaud
27 Jun 2024
Introduction to a review series on oncogenic signaling and immune evasion in hematologic malignancies
Robert Zeiser
Blood | VOL. 143
Robert ZeiserRobert Zeiser
27 Jun 2024
Crespiatico I, Zaghi M, Mastini C, et al. First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood. 2024;143(14):1399-1413.
-
Blood | VOL. 143
--
27 Jun 2024
View more papers